Children as young as six join Oxford vaccine trial
The single-blind, randomised phase II trial will include 300 volunteers. 240 participants will receive the ChAdOx1 nCoV-19 vaccine, while the remaining 60 will receive a control meningitis vaccine to act as a placebo.
The Oxford Vaccine – How generalisable are the trial results?
"Oxford-AstraZeneca has devised a vaccine in an unprecedented amount of time... However, with any and all science, it is important that we be critical of the claims being made, and question the scientific method used to arrive at such conclusions."
